Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
作者： Catherine Schairer , Jay Lubin , Rebecca Troisi , Susan Sturgeon , Louise Brinton
关键词: Gynecology 、 Mammary gland 、 Regimen 、 Cancer 、 Breast cancer 、 Risk factor 、 Hormone replacement therapy (menopause) 、 Menopause 、 Estrogen 、 Oncology 、 Medicine 、 Internal medicine
摘要: N A RECENT COLLABORATIVE REanalysis of more than 90% the world’s epidemiological data on relationship between menopausal hormone replacement therapy (HRT) and breast cancer risk, it was found that longer durations recent, but not past, use HRT increased particularly among leaner women for tumors were less clinically advanced. 1 Unresolved issues include extent to which findings due a biological effect hormones rather screening ascertainment. The also insufficient determine whether combined estrogen-progestin regimen risk beyond associated with estrogen alone. In 1994, we published
rejuvchip.com参考文章(14)
Ingemar Persson, Elisabete Weiderpass, Leif Bergkvist, Reinhold Bergström, Catherine Schairer, Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes & Control. ,vol. 10, pp. 253- 260 ,(1999) , 10.1023/A:1008909128110
Susan M. Gapstur, Monica Morrow, Thomas A. Sellers, Hormone Replacement Therapy and Risk of Breast Cancer With a Favorable Histology JAMA. ,vol. 281, pp. 2091- 2097 ,(1999) , 10.1001/JAMA.281.22.2091
Matti Poutanen, Veli Isomaa, Hellevi Peltoketo, Reijo Vihko, Role of 17β-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis The Journal of Steroid Biochemistry and Molecular Biology. ,vol. 55, pp. 525- 532 ,(1995) , 10.1016/0960-0760(95)00201-4
DF Hargreaves, F Knox, R Swindell, CS Potten, NJ Bundred, Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. British Journal of Cancer. ,vol. 78, pp. 945- 949 ,(1998) , 10.1038/BJC.1998.606
Louise A. Brinton, Robert N. Hoover, Moyses Szklo, Joseph F. Fraumeni, Menopausal estrogen use and risk of breast cancer Cancer. ,vol. 47, pp. 2517- 2522 ,(1981) , 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L
Catherine Schairer, Celia Byrne, Penelope M. Keyl, Louise A. Brinton, Susan R. Sturgeon, Robert N. Hoover, Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes & Control. ,vol. 5, pp. 491- 500 ,(1994) , 10.1007/BF01831376
Andrea Z LaCroix, Wylie Burke, Breast cancer and hormone replacement therapy. The Lancet. ,vol. 350, pp. 1042- 1043 ,(1997) , 10.1016/S0140-6736(97)22041-6
Thomas S. Rector, Exhaustion of Drug Benefits and Disenrollment of Medicare Beneficiaries From Managed Care Organizations JAMA. ,vol. 283, pp. 2163- 2167 ,(2000) , 10.1001/JAMA.283.16.2163
I J Laidlaw, R B Clarke, A Howell, A W Owen, C S Potten, E Anderson, The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone Endocrinology. ,vol. 136, pp. 164- 171 ,(1995) , 10.1210/ENDO.136.1.7828527
M. C. Pike, R. K. Ross, D. V. Spicer, Problems Involved in Including Women with Simple Hysterectomy in Epidemiologic Studies Measuring the Effects of Hormone Replacement Therapy on Breast Cancer Risk American Journal of Epidemiology. ,vol. 147, pp. 718- 721 ,(1998) , 10.1093/OXFORDJOURNALS.AJE.A009515